Xin Lang Cai Jing·2025-07-30 04:04Core Viewpoint - Baiyunshan (00874) has entered into a partnership agreement with Guangyao Capital to establish the second phase of the Guangyao Fund, aiming to enhance its investment in the biopharmaceutical sector and accelerate its strategic development in the healthcare industry [1]. Group 1: Company Actions - Baiyunshan's stock price increased by 2.65%, reaching HKD 18.60, with a trading volume of HKD 69.445 million [1]. - The company will invest RMB 1.4985 billion and Guangyao Capital will contribute RMB 1.5 million to the Guangyao Fund II [1]. - The financial performance of Guangyao Fund II will be consolidated into Baiyunshan's financial statements [1]. Group 2: Investment Focus - The partnership aims to conduct equity investments in the biopharmaceutical field, targeting investment returns [1]. - The fund will focus on investments in pharmaceuticals, medical devices, and healthcare services, aligning with the company's strategic planning [1]. - The establishment of Guangyao Fund II is intended to seize industry development opportunities and enhance the company's investment efforts in the biopharmaceutical and health sectors [1].